Open AccessBenefit-risk trade-offs in treatment choice in advanced HER2 negative breast cancer: patient and oncologist perspectives
Author(s) -
Suvina Amin,
Sara M. Tolaney,
M. Janelle CambronMellott,
Kathleen Beusterien,
Martine C. Maculaitis,
Emily Mulvihill,
Reshma Shinde,
Kimmie McLaurin
Publication year - 2022
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2021-0761
Subject(s) - medicine , breast cancer , nausea , quality of life (healthcare) , cancer , physical therapy , oncology , intensive care medicine , nursing
Aim: To evaluate which treatment attributes US patients and oncologists prioritize in HER2 negative advanced breast cancer (ABC). Methods: Preferences were assessed via a discrete choice experiment. Also, treatment goal statements were rated on an agreement scale. Results: Patients (n = 169) most valued improving overall survival (OS), followed by improving nausea and neuropathy. Oncologists (n = 117) most valued improving OS, followed by neuropathy and progression-free survival. Regarding treatment goals, oncologists (67%) perceived that patients are more focused on efficacy than quality of life; fewer patients (29%) agreed with this statement; 81% of oncologists and 51% of patients agreed that patients prefer oral treatment. Conclusion: Patients and oncologists were willing to accept increases in toxicities in exchange for efficacy improvements in HER2 negative ABC.